SEAGULL HEALTH
Your health,We care!
Olverembatinib Tablets can potently inhibit the T315I resistant mutation, with convenient administration and a controllable safety profile.
AuthenticGuaranteeFast DeliveryPrivacy On November 24, 2021, olverembatinib was approved for marketing, indicated
for the treatment of adult patients with chronic phase or accelerated phase
chronic myeloid leukemia (CML) who are resistant to any tyrosine kinase
inhibitor (TKI) and harbor the T315I mutation.
On November 16, 2023, olverembatinib obtained an approval update for the
treatment of adult patients with chronic phase chronic myeloid leukemia (CML-CP)
who are resistant and/or intolerant to first- and second-generation TKIs.
On January 17, 2024, a new indication for olverembatinib was approved, which
covers the treatment of adult patients with accelerated phase chronic myeloid
leukemia (CML-AP) who are resistant and/or intolerant to first- and
second-generation TKIs.
On May 6, 2022, Olverembatinib Tablets, a Class 1 novel drug independently developed by the Guangzhou Institutes of Biomedicine and Health (GIBH), Chi···【Read More】
Update: 20 Jan,2026Source: Haiou HealthViews: 98
On November 25, Olverembatinib Tablets (trade name: Nileck®), a Class 1 New Drug independently developed by the Guangzhou Institute of Biomedicine and···【Read More】
Update: 20 Jan,2026Source: Haiou HealthViews: 97
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
